Coloplast : Strong finish – Guidance incorporates risk factors
>Finish of 2020-21 even ahead of high expectations - Coloplast’s Q4 revenues of DKK 5,100m (+11.1% y-o-y) were up to 1% ahead of expectations driven by a strong organic growth of 10% (9%/10% ODDO BHF/consensus). Among the segments, Ostomy care achieved 10% organic growth and was 1%/2% ahead of expectations. The SenSura Mio portfolio and the Brava range of supporting products were the main contributors to growth. The SenSura Mio Convex solution was the main contri...Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.